ArticleJMIR public health and surveillance2025
The PrEP Pharmacy Reach Study: Protocol for the Creation of Maps to Visualize the Impact of Expanding Access to HIV Prevention Services Through Pharmacies.
Article in JMIR public health and surveillance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Potential Risks and Benefits of Low-Barrier Access and Monitoring for HIV Preexposure Prophylaxis: A Modeling Study.The Journal of infectious diseases · 2026Article
- The Potential Impact of Federal Funding Cuts on Access to Pre-Exposure Prophylaxis in Atlanta, Georgia: Geographic Modeling Study.JMIR public health and surveillance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Despite the proven efficacy of preexposure prophylaxis (PrEP) in reducing the risk of HIV transmission, uptake remains suboptimal among populations with limited access and availability to PrEP-prescribing locations, particularly in the Southern United States. The accessibility of pharmacies positions them as a promising resource for expanding PrEP delivery and access and supporting uptake and adherence through HIV prevention programs to reduce geographic disparities. Objective: This study outlines a geospatial protocol to assess disparities in national PrEP availability. The aim of this study is to develop a protocol to identify, map, and describe the potential impact of expanding PrEP access and HIV prevention services to pharmacies as alternative PrEP delivery sites across the United States. We propose a reproducible mapping and analytic framework to visualize gaps and inform implementation strategies at the state and local levels. Methods: We create local and state maps to help visualize the impact of expanding access to HIV prevention services through pharmacies. We obtain data from three main data sources: (1) pharmacy locations from the National Council for Prescription Drug Programs (NCPDP), (2) PrEP-prescribing facility locations from the CDC's National Prevention Information Network (NPIN), and (3) HIV case data per 100,000 persons from AIDSVu. We geocode pharmacies and PrEP-prescribing locations with Google application programming interfaces (APIs) via the ggmap package in R software. Maps are created by overlaying several different layers of general maps and aggregated data including base maps, choropleth maps, dot density maps. To quantitatively examine the potential impact of expanding HIV prevention services, we calculate a PrEP facility-to-need ratio (PfnR) as the total number of facilities (PrEP-prescribing or pharmacies) divided by the number of HIV cases per 100,000 persons. Fold-change estimates are computed to quantify the increase in service reach if pharmacies were incorporated into PrEP delivery. Results: Overall, maps depicted far greater availability of local pharmacies compared to PrEP-prescribing facilities. When considered in the context of HIV cases per 100,000 persons, pharmacies were more prevalent than PrEP-prescribing facilities in areas with higher HIV caseloads. Mean PfnRs for pharmacies ranged from 0.04 (Mississippi) to 1.3 (Alaska), while PrEP-prescribing facility PfnRs were as low as 0.0004 (Puerto Rico). Estimated fold-change increases ranged from 6.4 in Idaho to 120.3 in Puerto Rico, with the greatest increases in the Southern and Midwestern United States. Conclusions: This protocol provides a scalable and reproducible framework to assess PrEP service distribution and to identify areas which may benefit most from pharmacy integration. Our findings suggest that incorporating pharmacies into PrEP-delivery could substantially reduce geographic access barriers, especially in underserved regions. This work has critical implications for state and national policies focused on avenues to increase PrEP access and uptake and subsequently reduce HIV transmission in their regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.